Selectable stem cell modification for anti-HIV gene therapy using transient cell surface marking of modified cells using Modified CD4 molecule (CD4mod)

Technology #d-1356

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Green fluorescent protein (GFP) is a common in vitro cell surface marker, however, when incorporated in vivo, it can lead to unwanted immune responses. This ultimately leads to their elimination by the immune system.
 
The current technology uses modified CD4 as a cell surface marker to purify modified stem cells using immunomagnetic beads. This method both protects the marked cells from an immune response and maintains their viability.
 
Reference Number:

D-1356
 
Market Applications:
•Medical technologies
 
Features, Benefits, & Advantages:
•Lack of cytoplasmic tail prevents aberrant signaling
•Conditional expression of CD4 for selection
•Simplified process compared to GFP selection method
•While GFP may trigger an immune response, modCD4 will not
Intellectual Property:
A U.S. Provisional Patent application, Serial No. 62488972, was filed on 4/24/2017. Since then, a PCT, Serial No. US18/29213, has been filed on 4/24/2018
 
Development Stage:
The technology has been developed, and preliminary data is being generated.
 
Researchers:
Himanshu Garg, Ph. D., Associate Professor of Biomedical Sciences, Center of Emphasis in Infectious Diseases, Texas Tech University Health Sciences Center,  El Paso, Texas

Keywords:
TKSR39, immunomagnetic  beads, HIV, gene therapy, vector, (Tat-inducible) CD4, modified CD4